Bienville Capital Management LLC Sells 324,451 Shares of Omada Health, Inc. $OMDA

Bienville Capital Management LLC lowered its stake in shares of Omada Health, Inc. (NASDAQ:OMDA) by 36.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 573,314 shares of the company’s stock after selling 324,451 shares during the period. Omada Health accounts for approximately 1.7% of Bienville Capital Management LLC’s portfolio, making the stock its 20th largest holding. Bienville Capital Management LLC owned 0.94% of Omada Health worth $12,584,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in OMDA. Raymond James Financial Inc. bought a new position in Omada Health in the 2nd quarter worth about $32,000. Bellevue Group AG raised its position in shares of Omada Health by 0.7% during the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after buying an additional 1,791 shares in the last quarter. Quarry LP bought a new stake in shares of Omada Health during the 4th quarter worth $29,000. Barclays PLC increased its position in shares of Omada Health by 14.6% during the 4th quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after purchasing an additional 1,888 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in Omada Health by 319.3% in the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock worth $66,000 after buying an additional 2,283 shares in the last quarter.

Insider Activity

In related news, CAO Craig Gracey sold 1,042 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $25.00, for a total value of $26,050.00. Following the completion of the transaction, the chief accounting officer owned 15,441 shares of the company’s stock, valued at approximately $386,025. This represents a 6.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President Wei-Li Shao sold 8,866 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.02, for a total value of $221,827.32. Following the sale, the president directly owned 307,372 shares in the company, valued at approximately $7,690,447.44. This represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 277,406 shares of company stock valued at $5,907,726. 6.38% of the stock is owned by insiders.

Omada Health Trading Down 3.1%

Shares of OMDA stock opened at $21.50 on Thursday. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $26.92. The stock has a market cap of $1.32 billion, a P/E ratio of 430.00 and a beta of 1.86. The company has a 50 day simple moving average of $22.70 and a two-hundred day simple moving average of $17.84.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The firm had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. As a group, equities analysts forecast that Omada Health, Inc. will post 0.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on OMDA. JPMorgan Chase & Co. lifted their price target on shares of Omada Health from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Weiss Ratings upgraded Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Citizens Jmp lifted their price target on shares of Omada Health from $27.00 to $32.00 and gave the company a “market outperform” rating in a research report on Friday, August 14th. Citigroup reissued an “outperform” rating on shares of Omada Health in a report on Friday, August 14th. Finally, Robert W. Baird increased their target price on Omada Health from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.50.

Omada Health Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.